CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion

This article is the result of a round-table discussion organised by ESMO Open in Vienna in December 2017. Its purpose is to discuss the background and advances in the evidence regarding cyclin-dependent kinase 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) in the treatment of metastatic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Preusser, Matthias, De Mattos-Arruda, Leticia, Thill, Marc, Criscitiello, Carmen, Bartsch, Rupert, Ruhstaller, Thomas, de Azambuja, Evandro, Zielinski, Christoph C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109817/
https://www.ncbi.nlm.nih.gov/pubmed/30167331
http://dx.doi.org/10.1136/esmoopen-2018-000368
_version_ 1783350385352638464
author Preusser, Matthias
De Mattos-Arruda, Leticia
Thill, Marc
Criscitiello, Carmen
Bartsch, Rupert
Ruhstaller, Thomas
de Azambuja, Evandro
Zielinski, Christoph C
author_facet Preusser, Matthias
De Mattos-Arruda, Leticia
Thill, Marc
Criscitiello, Carmen
Bartsch, Rupert
Ruhstaller, Thomas
de Azambuja, Evandro
Zielinski, Christoph C
author_sort Preusser, Matthias
collection PubMed
description This article is the result of a round-table discussion organised by ESMO Open in Vienna in December 2017. Its purpose is to discuss the background and advances in the evidence regarding cyclin-dependent kinase 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) in the treatment of metastatic and early-stage breast cancer and to explore what the key open research questions are and next steps should be.
format Online
Article
Text
id pubmed-6109817
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-61098172018-08-30 CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion Preusser, Matthias De Mattos-Arruda, Leticia Thill, Marc Criscitiello, Carmen Bartsch, Rupert Ruhstaller, Thomas de Azambuja, Evandro Zielinski, Christoph C ESMO Open Review This article is the result of a round-table discussion organised by ESMO Open in Vienna in December 2017. Its purpose is to discuss the background and advances in the evidence regarding cyclin-dependent kinase 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) in the treatment of metastatic and early-stage breast cancer and to explore what the key open research questions are and next steps should be. BMJ Publishing Group 2018-08-20 /pmc/articles/PMC6109817/ /pubmed/30167331 http://dx.doi.org/10.1136/esmoopen-2018-000368 Text en © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
Preusser, Matthias
De Mattos-Arruda, Leticia
Thill, Marc
Criscitiello, Carmen
Bartsch, Rupert
Ruhstaller, Thomas
de Azambuja, Evandro
Zielinski, Christoph C
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
title CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
title_full CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
title_fullStr CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
title_full_unstemmed CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
title_short CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
title_sort cdk4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109817/
https://www.ncbi.nlm.nih.gov/pubmed/30167331
http://dx.doi.org/10.1136/esmoopen-2018-000368
work_keys_str_mv AT preussermatthias cdk46inhibitorsinthetreatmentofpatientswithbreastcancersummaryofamultidisciplinaryroundtablediscussion
AT demattosarrudaleticia cdk46inhibitorsinthetreatmentofpatientswithbreastcancersummaryofamultidisciplinaryroundtablediscussion
AT thillmarc cdk46inhibitorsinthetreatmentofpatientswithbreastcancersummaryofamultidisciplinaryroundtablediscussion
AT criscitiellocarmen cdk46inhibitorsinthetreatmentofpatientswithbreastcancersummaryofamultidisciplinaryroundtablediscussion
AT bartschrupert cdk46inhibitorsinthetreatmentofpatientswithbreastcancersummaryofamultidisciplinaryroundtablediscussion
AT ruhstallerthomas cdk46inhibitorsinthetreatmentofpatientswithbreastcancersummaryofamultidisciplinaryroundtablediscussion
AT deazambujaevandro cdk46inhibitorsinthetreatmentofpatientswithbreastcancersummaryofamultidisciplinaryroundtablediscussion
AT zielinskichristophc cdk46inhibitorsinthetreatmentofpatientswithbreastcancersummaryofamultidisciplinaryroundtablediscussion

Ejemplares similares